期刊文献+

辛伐他汀对人单核源树突状细胞成熟及免疫功能影响的研究 被引量:2

On effects of simvastatin on human monocyte derived DCs mature and its on immunological functions
下载PDF
导出
摘要 目的:探讨辛伐他汀对人单核源树突状细胞(Dendritic cell,DC)成熟和免疫功能的影响。方法:梯度离心法分离人外周血单核细胞(peripheral blood monouclear cells,PBMC),经含重组人粒细胞-巨噬细胞集落刺激因子(recombinant human granulocyte-macrophage colony-stimulating factor,rhGM-CSF)和重组人白介素-4(recombinant human interleukin-4,rhIL-4)的Cellgro培养,使其分化为DC。以PBS组作阴性对照,LPS组作阳性对照,将DC与Dil染料标记的氧化低密度脂蛋白共同孵育48 h及DC与100μmol/L辛伐他汀和50 mg/L DiI染料标记的氧化低密度脂蛋白(oxy-Low Density Lipoprotein,0x-LDL)共同孵育48 h作实验组,流式细胞术(Fluorescence Activated Cell Sorting,FACS)检测DC表型(CDla、CD80、CD86、HLA-DR)的表达,同时镜下观察DC吞噬0x-LDL的形态变化。结果:经辛伐他汀处理的DC可下调CDla、HLA-DR的表达,抑制DC对0x-LDL的吞噬作用。结论:辛伐他汀可明显抑制DC的免疫活性,他汀类药物可能具有免疫调节的新机制。 Objective: To investigate the effects of simvastatin on human monocyte derived DCs mature and its on immunological functions. Methods: Human monoeytes were isolated by means of gradient centrifugatinn method, followed by 5 days' culture with DC Cellgro medium containing 100ng/ml rhGM -CSF and 20ng/ml rhlL- 4. Mature DCs was then obtained. DBS and LPS were as the negative and positive control, and in experimental groups, antigen as Ox - LDL labelled with 50 μg/mlDil were added to the medium both to iucubate with DCs, while drug as 100 μmol/L simvastatin was only added to one group. FACS was used to investigate the immuno - phenotypic expression( CDI a, CD50, CD86 and HLA - DR) after 48 hours. The progress of phagocytosis was observed in microscope, and the effects of DCs on lymphocyte proliferation was observed by mixed T lymphocyte reaction. Results: Atorvastatin reduced DCs' immuno - phenotypic expressions of CD 1 a and HLA - DR, and inhibited DCs' Phagocytosis of 0x - LDL. Conclusion: Simvastatin can significantly inhibit immune activity and the function of phagocytosis of DCs, which shows a new immune regulating mechanism of statins series.
出处 《河南大学学报(医学版)》 CAS 2007年第4期19-22,共4页 Journal of Henan University:Medical Science
基金 广东省中山市科技攻关项目(206A039)
关键词 辛伐他汀 树突状细胞 吞噬 免疫功能 Simvastatin Dendritic cell Phagocytosis Immunological function
  • 相关文献

参考文献17

  • 1Takemoto M, LiaoJK. Pleiotropic effects of 3 - hydroxy - 3 - methylglutaryl coenzyme a reductase inhibitots [ J ]. Arterioscler Thromb Vase Biol,2001,21 ( 11 ) : 1712-1719.
  • 2Kobashigawa JA,Katznelson S, Laks H, et al. Effect of pravastatinon outcomes after cardiac transplantation [ J ]. N Engl J Med, 1995,333(10) :621-627.
  • 3Hansson GK, Libby P, Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of at herosclerosis [ J ]. Circ Res, 2002,91:281-291.
  • 4Bobryshev YV, Lord RS. S - 100 positive celis in human arterial intima and in atherosclerotic lesions [ J ]. Cardiovasc Res, 1995,29 (5) :689-696.
  • 5Cao X,Zhang W,He L, et al. lymphotactin gene - modified bone marrow dendritic cellS act as more potent adjuvants for peptide delivery to induce specific antitumor immunity [ J ]. Immunol, 1998,161:6238-6244.
  • 6Hakkinen T, Karkola K, Yla- Herttuala S. Macrophages,smooth muscle cells,endothel ial cells,and T- cel 1 s express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions:colocalization with epitopes of oxidized low - density lipoprotein, scavenger receptor, and CD16 ( FcRIII ) [ J ]. Virchows Arch,2000,437 (4) : 396-405.
  • 7Schonbeck U, Gerdes N, Varo N, et al. Oxidized low - density lipoprotein augments and 3 - hydroxy - 3 - methylglutaryl coenzyme. A reductase inhibittors limit CD40 and CD40L expression in human vascular cells [ J ]. Circulation,2002,106 (23) : 162.
  • 8Ehara S, Ueda M, Naruko T,et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronery syndromes [ J ]. Circulation,2001,103 ( 15 ) : 1955-1960.
  • 9Rohan RM, Fernandez A, Udagawa T,et al. Genetic heterogeneity of angiogenesis in mice[ J ]. FASEB J,2000,14(7) :871-876.
  • 10Landmesser U,Harri son DG. Oxidant stress as a marker for cardiovascular events: Oxmarks the spot [ J ]. Circulation,2001,104 (22) :2638-2640.

二级参考文献37

共引文献45

同被引文献18

  • 1仲琳,张运,张梅,季哓平,陈文强,姚桂华,丁士芳,张鹏飞.兔动脉粥样硬化易损斑块模型的建立[J].基础医学与临床,2005,25(4):370-374. 被引量:30
  • 2陶忠芬,蔡永国,杨仕明,可金星,黄文琪,肖桃元,房殿春.树突状细胞扫描电镜样本制备方法[J].第三军医大学学报,2005,27(12):1299-1300. 被引量:12
  • 3缪绯,刘映峰,傅强,李志梁,李公信,吴宏超,徐琳.阿托伐他汀对外周血中树突状细胞成熟及免疫功能的影响[J].中国医科大学学报,2007,36(3):265-267. 被引量:4
  • 4HPS Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high risk individuals:a randomised placebo-controlled trial[J]. Lancet, 2002,360 (1): 7.
  • 5Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER) : a randomised controlled trial[J]. Lancet, 2002,360 (10) :1623.
  • 6Sever PS,Dahl B,Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial, lipid lowering arm(ASCOT-LLA):a multicentre randomised controlled trial[J]. Lancet, 2003,361 (8):1149.
  • 7Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators, intensive versus moderate lipid lowering with statins after acute coronary syndromes[J]. N Engl J Med, 2004,350(7) :1495.
  • 8Amarenco P, Bogousslavsky J, Callahan A, et al. Stroke prevention by aggressive reduction in cholesterol levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med, 2006,352 (2) :549.
  • 9The SPARCL Investigators. Design and baSeline characteristics of the stroke prevention b.y aggressive reduction in cholesterol levels (SPARCL) study[J]. Cerebrovasc Dis, 2003,16 (2) : 389.
  • 10潘华,王大伟,李红波,张志伟.密度梯度离心与贴壁法相结合体外分离培养兔骨髓基质干细胞:1~3代细胞生长特性[J].中国组织工程研究与临床康复,2007,11(42):8487-8490. 被引量:13

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部